Allergy Diagnostics Market Size & Share Analysis - Trends, Drivers, Competitive Landscape, and Forecasts (2025 - 2032)

Allergy Diagnostics Market Dynamics

Technological Advancements Are Revolutionizing Diagnostic Capabilities

• The integration of artificial intelligence, machine learning algorithms, and molecular diagnostics is transforming allergy diagnosis by improving accuracy, speed, and predictive analysis capabilities.
• Modern diagnostics platforms now incorporate automated systems that process hundreds of samples daily with minimal technician oversight, while embedded AI algorithms read complex profiles and flag clinically relevant cross-reactivity patterns.
• Component-resolved diagnostics (CRD) technology represents a significant advancement, moving from niche applications to mainstream adoption.
• This technology improves accuracy in differentiating true sensitization from cross-reactivity, enabling more precise treatment planning.
• Multiplex testing capabilities allow concurrent analysis of numerous allergens from a single patient sample, reducing costs and improving efficiency.
• The European Medicines Agency reports a growing adoption of point-of-care testing solutions that provide rapid results, convenience, and cost-effectiveness.
• The Development of handheld immunoassay devices and biosensors is reducing dependence on central laboratories, while telemedicine integration extends healthcare access to rural and underserved regions.
• According to the American Medical Association, telehealth service utilization increased to 85% in 2022 from 75% in 2021, marking significant growth in remote diagnostic capabilities.

Rising Prevalence of Allergic Conditions Is Driving Market Growth

• The escalating incidence of allergic diseases globally represents the primary driver for the allergy diagnostics market expansion.
• Multiple factors contribute to this trend, including environmental pollution, changing dietary patterns, and increased exposure to indoor and outdoor allergens.
• According to the American Academy of Allergy, Asthma, and Immunology (AAAAI), allergies rank as the sixth most-common chronic ailment in the U.S., impacting nearly 50 million individuals annually.
• Air pollution has emerged as a critical factor influencing allergy prevalence.
• Urban populations demonstrate significantly higher allergy rates compared to rural communities due to exposure to industrial pollutants and vehicle emissions.
• According to the United Nations, about 55% of the world’s population lived in urban areas in 2018, with projections for this share to rise to 68% by 2050.
• This will leave more people susceptible to the negative consequences of air quality deterioration.
• The CDC estimates show that approximately 32 million people in the U.S. suffer from food allergies.
• Childhood food allergy prevalence is increasing at a rate of 2.1% per decade among Black Americans and 1.2% per decade among Hispanic Americans.
• Climate change also contributes to extended pollen seasons, with the AAAAI noting that exposure to pollen has increased due to longer and more-intense pollen seasons, particularly in urban environments.
• Adverse drug reactions affect 10% of the world population, contribute to around 20% of the hospitalized patients, and account for 20% of the fatalities due to anaphylaxis, as per the AAAAI.

High Costs of Diagnostic Technologies Pose Market Challenges

• The substantial costs associated with advanced allergy diagnosis procedures represent a significant barrier to market expansion, particularly limiting accessibility for patients in developing regions and smaller healthcare facilities.
• Advanced diagnostic technologies, including molecular testing, next-generation sequencing, and automated multiplex platforms, require considerable capital investments that many healthcare providers struggle to accommodate.
• The Centers for Medicare & Medicaid Services data from 2023 reveals that in-vivo skin prick testing reimbursement stands at 7–9 USD per procedure, while in-vitro blood tests command fees of 15-20 USD, creating cost pressures for both providers and patients.
• These pricing disparities affect test selection and accessibility, particularly in cost-sensitive markets where budget constraints limit diagnostic options.

Allergy Diagnostics Market Segmentation Analysis

Offering Analysis

The consumables category held the largest share in the allergy diagnostics market in 2024, of 55%, and it is expected to retain its dominant position in the coming years. This dominance is primarily attributed to the recurring need for reagents, test kits, and disposable materials essential for routine and repetitive allergy testing procedures. Consumables demonstrate cost-effectiveness compared to instruments, making them accessible to a broader range of healthcare facilities and patients.

The instruments category will witness the highest CAGR during the forecast period, driven by the continuous advancements in automation, enhanced testing efficiency, and integration of artificial intelligence for data analysis. Modern instruments offer high-throughput capabilities, multiplex testing options, and precise diagnostic accuracy, which enables comprehensive allergy diagnosis and management. The adoption of sophisticated testing platforms facilitates simultaneous detection of multiple allergens, improving laboratory productivity and patient outcomes.

These offering categories are covered:

• Consumables (Largest Category)
  • Test kits
  • Reagents
  • Assay plates
  • Disposable materials
• Instruments (Fastest-Growing Category)
  • Immunoassay analyzers
  • ELISA analyzers
  • Luminometers
• Services
  • Testing services
  • Consultation
  • Result interpretation

Allergen Analysis

The inhaled allergens category dominated the allergy diagnostics market in 2024, accounting for 60% market share, due to the widespread prevalence of respiratory allergies and environmental factors. Rising air pollution, industrialization, and urbanization have significantly increased exposure to airborne allergens, including pollen, dust mites, mold spores, and pet dander. According to the Asthma and Allergy Foundation of America, seasonal allergic rhinitis affects 81 million Americans, with approximately 26% of adults and 19% of children experiencing symptoms. Globally, allergic rhinitis affects between 10% and 30% of the population, says the AAAAI.

The food allergens category is expected to register the highest CAGR during the forecast period, driven by increasing awareness of food allergies and their potential health impacts. The Food Allergy Research and Education organization reports that approximately 32 million Americans have food allergies, with 5.6 million children under age 18 affected. Public health campaigns and educational initiatives have heightened awareness about food allergies, leading to greater demand for accurate diagnostic testing. Shellfish, peanuts, and cow milk are among the most-common food allergens worldwide.

These allergen types are covered:

• Inhaled (Largest Category)
  • Pollen
  • Dust mites
  • Pet dander
  • Mold spores
• Food (Fastest-Growing Category)
  • Peanuts
  • Tree nuts
  • Shellfish
  • Dairy products
  • Eggs
• Drug
  • Antibiotics
  • NSAIDs
  • Other medications

Test Type Analysis

The in-vivo category held the larger market share, of 60% in 2024, primarily due to cost-effectiveness, immediate results, and widespread clinical adoption. In-vivo techniques, including skin prick tests, intradermal tests, and patch tests, provide immediate allergic responses that enable diagnosis of multiple allergens simultaneously. According to Centers for Medicare & Medicaid Services, in-vivo skin prick testing reimbursement stands at 7-9 USD per procedure, making it particularly valuable in cost-sensitive markets.

The in-vitro category is projected to grow at the higher CAGR during the forecast period due to enhanced safety profiles, technological advancements, and patient preference for blood-based testing. In-vitro tests eliminate exposure risks and accommodate patients with compromised skin conditions or those taking medications that interfere with skin testing. These tests utilize allergen-specific immunoglobulin E detection methods that offer higher positive predictive value and superior specificity for detecting aeroallergen sensitization.

These test types are covered:

• In-Vivo (Larger Category)
  • Skin prick tests
  • Intradermal tests
  • Patch tests
• In-Vitro (Faster-Growing Category)
  • IgE-specific tests
  • Component-resolved diagnostics

End User Analysis

The diagnostic laboratories category captured the largest share, of 55%, in 2024, driven by specialized expertise, advanced equipment capabilities, and high testing volumes. Diagnostic laboratories offer comprehensive allergy testing services with state-of-the-art technologies and expert personnel who specialize in accurate allergy testing procedures. These facilities provide shorter wait times than hospitals and house advanced technologies for precise allergen identification.

Academic research institutions are the fastest-growing category, driven by increased investment in translational research, a rising focus on personalized medicine, and advancements in molecular allergen identification. Collaborations between universities and biotech firms are accelerating innovation, while funding from government and private sources supports cutting-edge studies. As allergy prevalence rises globally, academic centers are playing a crucial role in developing novel diagnostic tools and improving the scientific understanding of allergic diseases.

These end users are covered:

• Diagnostic Laboratories (Largest Category)
• Hospital-Based Laboratories
• Academic Research Institutes (Fastest-Growing Category)

Allergy Diagnostics Market Regional Outlook

North America Allergy Diagnostics Market Size

North America held the largest share, of 45%, in 2024, and it is expected to maintain its leadership position throughout the forecast period. This dominance is attributed to advanced healthcare infrastructure, high prevalence of allergic conditions, substantial R&D investments, and favorable reimbursement policies. The Allergy & Asthma Network reports that more than 50 million Americans suffer from allergies, with 11% of adults and 71% of children dealing with food allergies.

The region benefits from the presence of leading market players, widespread adoption of advanced diagnostic technologies, and strong public awareness about allergy management. Government funding for allergy research and the establishment of specialized allergy care facilities further support market growth. According to the CDC, the U.S. experiences approximately 200,000 emergency department visits annually for anaphylaxis-related incidents, highlighting the critical need for accurate diagnostic solutions.

Asia-Pacific Allergy Diagnostics Market Forecast

Asia-Pacific is expected to register the highest CAGR, of %, during 2025–2032, driven by rapid urbanization, increasing pollution levels, and growing healthcare awareness. The region demonstrates significant potential due to expanding healthcare infrastructure, rising disposable incomes, and lifestyle changes contributing to increased allergy prevalence.

China represents the largest country market within the region, with swift growth attributed to soaring healthcare expenses, amplifying allergy awareness, and innovations in diagnostic tools. The World Allergy Organization reports that allergic diseases are rising rapidly in Asia, with urbanization and pollution serving as primary contributing factors. Countries, including India, Japan, and Australia, are expanding healthcare access and adopting advanced diagnostic technologies, creating substantial opportunities for market players.

These regions and countries are covered:

• North America (Largest Regional Market)
  • U.S. (Larger Country Market)
  • Canada (Fastest-Growing Country Market)
• Europe
  • Germany (Largest Country Market)
  • U.K. (Fastest-Growing Country Market)
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific (Fastest-Growing Regional Market)
  • China (Largest Country Market)
  • India (Fastest-Growing Country Market)
  • Japan
  • Australia
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil (Largest Country Market)
  • Mexico (Fastest-Growing Country Market)
  • Rest of LATAM
• Middle East & Africa
  • Saudi Arabia (Largest Country Market)
  • South Africa (Fastest-Growing Country Market)
  • Rest of MEA

Allergy Diagnostics Market Share Analysis

The allergy diagnostics market demonstrates a moderately consolidated structure with several established players maintaining significant market presence alongside emerging companies focusing on innovative diagnostic solutions. The market is characterized by continuous technological advancement, strategic partnerships, and ongoing product development initiatives aimed at enhancing diagnostic accuracy and expanding testing capabilities.

Leading companies, including Thermo Fisher Scientific, Siemens Healthineers, Danaher Corporation, and bioMérieux, collectively account for an approximately 30% global market share. These companies leverage extensive product portfolios, global distribution networks, and substantial R&D investments to maintain competitive advantages. Their market positions are strengthened through comprehensive diagnostic platforms that integrate multiple testing methodologies and advanced analytical capabilities.

The competitive landscape is marked by frequent product launches, strategic collaborations, and acquisitions among key players. Companies are increasingly focusing on developing multiplex assays, automated testing platforms, and AI-driven analytical solutions to meet evolving market demands. The integration of digital health technologies and telemedicine capabilities represents a growing trend among market participants seeking to expand their service offerings.

Market consolidation activities continue as larger companies acquire specialized diagnostic firms to enhance technological capabilities and expand geographic presence. Smaller companies and emerging players are focusing on niche applications, innovative testing methodologies, and point-of-care solutions to establish market footing and compete with established entities.

Allergy Diagnostics Market News

• In April 2025, Danaher Corporation unveiled its next-generation basophil activation test (BAT), designed to expedite and improve the study of allergies for research purposes.
• In March 2025, Bern-based biotechnology startup ATANIS Biotech AG received USD 2 million in funding to expedite commercialization and clinical implementation as part of Phase 2 of the FARE Innovation Award Diagnostic Challenge. Following a thorough scientific assessment, Food Allergy Research & Education (FARE) chose the company’s FAST-PASE allergy test, which is a functional ex vivo mast cell activation assay.
• In July 2024, AliveDx Suisse SA received the IVDR CE mark certification for its microarray immunoassay, which detects specific IgE protein allergens. This certification enhances the diagnostic accuracy of allergy tests in European markets.
• In January 2024, Inimmune Corporation and Intrommune Therapeutics Inc. announced a strategic collaboration to develop novel oral mucosal immunotherapy treatments for allergies, advancing innovative approaches in allergy management.
• In October 2023, ALK-Abelló A/S introduced its new range of allergy skin testing devices—AllerTest-1, -8, and -10. These devices are designed to improve diagnostic efficiency and streamline clinical workflows in allergy testing.